Recently, CGeneTech announced the first close of its over CNY 100 million Series C financing round. The funds raised will be used for the commercial production and sales of the company's upcoming Class 1 innovative drug product, Sengliptin (formerly known as Shengliptin), as well as for the clinical development of its subsequent innovative product pipeline.

CGeneTech is a biotechnology company at the commercialization stage, with a core team possessing decades of international experience in the entire lifecycle of pharmaceuticals. It is committed to the research and industrialization of high-quality and differentiated small molecule innovative drugs. Leveraging an integrated drug discovery technology platform and diverse commercial perspectives, the company has established a rich pipeline of innovative drugs covering areas such as blood sugar reduction, cancer treatment, and autoimmune diseases.

Currently, CGeneTech's independently developed next-generation highly selective DPP-4 inhibitor, Cenglitin, is about to be approved for marketing. Clinical results show that compared with similar drugs already on the market, its "half the dose, double the effect" treatment outcomes are expected to make it the best-in-class hypoglycemic drug. More importantly, its safety profile further addresses common adverse reactions found in currently marketed products.

EndoCell Completes Pre-A+ Round Financing for Regenerative Islet Technology

Recently, EndoCell completed the Pre-A+ round of financing, which will be mainly used for preclinical research and the launch of clinical phases I and II. This round of financing was jointly invested by Panlin Capital, Leo Capital, and Jintai Jinhong.

EndoCell, established in 2019 and located in Minhang District, Shanghai, is led by Researcher Cheng Xin from the Center for Excellence in Molecular Cell Science of the Chinese Academy of Sciences. The R&D team under his leadership has deep technical expertise and extensive research experience in the fields of in vitro directed differentiation of stem cells and in vitro regeneration of tissues and organs. The company focuses on the in vitro reconstruction of human tissues and organs, with its first pipeline being regenerative islets, which hold promise for transplantation therapy in diabetes characterized by islet damage.

Shenzhen Aipuyu Pharmaceutical Technology Co., Ltd. Completes Angel Round Financing

Recently, Shenzhen Aipuyu Pharmaceutical Technology Co., Ltd. (Aipuyu Pharmaceutical) announced the completion of its angel round financing. This round was jointly invested by Phoenix Pharmaceutical Group and the Dubai Stellar International Enterprise Investment Cooperation Committee (SIEIC). The proceeds will primarily be used for the development and upgrading of the dual-heart treatment traditional Chinese medicine "Rijiantong," the high-end kidney-tonifying traditional Chinese medicine "Kuilongdan," as well as brand building and channel development. Strong Cloud Capital served as the financial advisor for this round of financing.

Aipuyu Pharmaceutical, established in 2022, is an innovative pharmaceutical company integrating technology research and development, drug manufacturing, brand operation, and marketing. The company has several wholly-owned and joint venture subsidiaries, including Jilin Aipuyu Pharmaceutical Co., Ltd. and Aipuyu Natural Medicine International Co., Ltd. Its portfolio includes several star products such as "Kuilongdan," "Rijiantong Xinshu Capsules," "Shouyanshu Zaizao Pills," and "Jierunsi Mei Anti-HPV Gynecological Gel." The product range covers various dosage forms including capsules, pills, pellets, and powders, spanning multiple therapeutic areas such as cardiovascular, reproductive system, digestive system, anti-tumor, and anti-aging treatments, with exclusive national formulations and drug approvals in China.

Tiantan Biologics Over 1.3 Billion Yuan Mega Acquisition! Haier, Boya, Pailin, What's the Next Move in the Blood Products Industry?

Heavyweight Oral Hypoglycemic Drug Collection Procurement Imminent, Patent Expiration! 30 Pharmaceutical Companies Including CT Tianqing, Wanbang, Dongyangguang, and Qilu Challenge Merck's Monopoly

August Earnings Season for Listed Companies: Luye, Yifan, and Pien Tze Huang Shine with Strong Results; Xingqi's Stock Price Plummets; Senior Management Changes at Hengrui, Innovent, and Rongchang

www.yyjjb.com.cn

Insight into Industry Trends

Long press to followPharmaceutical Economy News

"Pharmaceutical Economy News"

Academic Official Account

Focusing on the Frontier of Oncology Academia

Long press to followImmunity Period

《Pharmaceutical Economy News》

Terminal Official Account

Record Major Events in the Pharmaceutical Industry

Long press to follow21st Century Pharmacy